What is HC Wainwright’s Forecast for Genelux Q1 Earnings?

Genelux Co. (NASDAQ:GNLX) – Equities research analysts at HC Wainwright cut their Q1 2025 earnings per share (EPS) estimates for shares of Genelux in a report released on Monday, March 31st. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.25) per share for the quarter, down from their previous forecast of ($0.16). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.03) EPS, FY2026 earnings at ($1.03) EPS, FY2027 earnings at ($0.76) EPS, FY2028 earnings at $0.32 EPS and FY2029 earnings at $1.32 EPS.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09).

Genelux Trading Down 4.4 %

NASDAQ:GNLX opened at $2.39 on Thursday. The company has a market capitalization of $83.00 million, a P/E ratio of -2.52 and a beta of -1.41. The firm has a 50-day moving average price of $4.00 and a two-hundred day moving average price of $3.10. Genelux has a twelve month low of $1.60 and a twelve month high of $5.89.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Geode Capital Management LLC lifted its stake in Genelux by 39.7% in the 3rd quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock valued at $749,000 after buying an additional 89,854 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Genelux by 51.4% in the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company’s stock valued at $368,000 after acquiring an additional 52,958 shares in the last quarter. LPL Financial LLC increased its position in Genelux by 72.3% during the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock worth $222,000 after purchasing an additional 39,516 shares in the last quarter. LifeSteps Financial Inc. increased its position in Genelux by 11.1% during the 4th quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock worth $205,000 after purchasing an additional 8,715 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Genelux in the 3rd quarter valued at about $59,000. 37.33% of the stock is owned by hedge funds and other institutional investors.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.